TRCT
CRDL

Tower Research Capital (TRC)’s Cardiol Therapeutics CRDL Stock Holding History

Tower Research Capital (TRC)’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-118
Closed -$114 – 5297
2025
Q1 		$114 Buy
+118
New +$145 ﹤0.01% 5023
2023
Q1 		– Sell
-22,456
Closed -$11K – 5869
2022
Q4 		$11K Buy
22,456
+18,926
+536% +$11.5K ﹤0.01% 3798
2022
Q3 		$4K Sell
3,530
-983
-22% -$1.2K ﹤0.01% 5236
2022
Q2 		$6K Buy
4,513
+3,323
+279% +$4.73K ﹤0.01% 4906
2022
Q1 		$2K Buy
1,190
+929
+356% +$1.53K ﹤0.01% 5525
2021
Q4 		$0 Sell
261
-1,900
-88% -$5.25K ﹤0.01% 6185
2021
Q3 		$9K Buy
+2,161
New +$7.83K ﹤0.01% 4423

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return

Tower Research Capital (TRC)'s CRDL Position: Q2 2025 in Review

Tower Research Capital (TRC) sold out of Cardiol Therapeutics (CRDL) in Q2 2025, closing a stake of 118 shares — an estimated $114 sold.

Tower Research Capital (TRC) first reported a position in CRDL in Q3 2021 and held it in 7 quarters. The position peaked at $11K in Q4 2022. 38 funds tracked by Wall St. Rank hold CRDL as of Q2 2025.

  • Tower Research Capital (TRC) reported no remaining Cardiol Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 118 Cardiol Therapeutics shares in Q2 2025, an estimated $114.
  • Tower Research Capital (TRC) first reported a position in Cardiol Therapeutics in Q3 2021 and held it in 7 quarters.
  • Tower Research Capital (TRC)'s Cardiol Therapeutics position peaked at $11K in Q4 2022.
  • 38 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.